Shots:
- Taiho Pharmaceutical has exercised its option to develop & commercialize casdatifan, pending approval in Japan & other Asian regions (excl. Greater China) under Taiho & Arcus’ 2017 option & license agreement
- As per the deal, Arcus will receive an option exercise payment & clinical, regulatory, plus commercial milestone payments, with net sales-based royalties. Although financial terms remain unknown
- Casdatifan (HIF-2α inhibitor) is being evaluated in the ongoing P-III (PEAK-1) trial in combination with a VEGFR-targeted TKI vs VEGFR-targeted TKI monotx. in pts with clear cell renal cell carcinoma; the study is expected to initiate in Japanese pts by H1’26
Ref: Taiho Pharmaceutical | Image: Taiho and Arcus Biosciences | Press Release
Related News:- Taiho Oncology (Part of Taiho Pharmaceutical) Reports the US FDA’s sNDA Acceptance of Inqovi + Venetoclax for Newly Diagnosed AML
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
